Recent studies have implicated local inflammation and complement activation in the pathogenesis of age-related macular degeneration (AMD) and geographic atrophy. It has been suggested that amyloid beta is linked to these local inflammatory processes, identifying it as a potential interventional target to reduce inflammatory response and limit the progression of geographic lesions. This video briefly details data presented at this year’s ARVO congress, in Seattle, US (Wednesday 04 May 2016, 09:00-09:15 PM, Session 403). Authors Lashkari et al. from the Schepens Eye Institute, USA concluded that the amyloid beta plasma levels were significantly higher in patients with geographic atrophy, supporting the hypothesis that targeting amyloid beta may help reduce the progression of geographic atrophy.
Systemic levels of amyloid β
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
